Latest / What the Flux / ResMed investors sleep soundly | Figma pops 250% on IPO | Ozempic faces a new challenger

Transcript

ResMed investors sleep soundly | Figma pops 250% on IPO | Ozempic faces a new challenger · What the Flux

• 0:05
  Speaker 1: This is what the Flux I'm brand and I'm justin
• 0:07
  Speaker 1: and a Monday, the fourth of August does it.
• 0:09
  Speaker 2: Australia has been spared by the US in the tariff walls,
• 0:13
  Speaker 2: well kind of, you see. Back in April, Trump whacked
• 0:16
  Speaker 2: a ten percent reciprocal tariff on all Australian goods exploded
• 0:19
  Speaker 2: into the US and then said he'll make a decision
• 0:21
  Speaker 2: whether to increase it in ninety days. Well, ninety days
• 0:24
  Speaker 2: has coming gone, and Trump has decided to keep Australia's
• 0:27
  Speaker 2: tariff at ten percent. Okay, And while it's not necessarily
• 0:30
  Speaker 2: good news to pay this new ten percent tariff, it's
• 0:32
  Speaker 2: certainly not as bad as India's twenty five percent or
• 0:34
  Speaker 2: Canada's thirty five percent.
• 0:36
  Speaker 1: That's really got a hot flam. If you've been promising
• 0:39
  Speaker 1: yourself that you want to get on top of your spending,
• 0:40
  Speaker 1: see where your money's going, at the beginning of the
• 0:42
  Speaker 1: month is the perfect time to do it. And we've
• 0:44
  Speaker 1: just ticked over into August. The Flux Budgeting TOIL helps
• 0:47
  Speaker 1: you track all your spending in the one spot. It
• 0:49
  Speaker 1: categorizes all your expenses. You can see where you're spending,
• 0:52
  Speaker 1: how much is spending. So if you want to start
• 0:53
  Speaker 1: tracking your money better so you can save more, make
• 0:55
  Speaker 1: sure to download the Flux app and check out the
• 0:57
  Speaker 1: budgeting tool.
• 0:58
  Speaker 2: Three distinctive stories today juzzy boy, let's do it for
• 1:01
  Speaker 2: our first. ResMed has beaten full year earnings and its
• 1:05
  Speaker 2: revenue forecast, thank you to a growth in snores around
• 1:09
  Speaker 2: the world.
• 1:09
  Speaker 1: It's like bedtime just got serious. B man financially speaking,
• 1:12
  Speaker 1: of course, so tell me what okay so.
• 1:14
  Speaker 2: ResMed was founded back in nineteen eighty nine by scientist
• 1:17
  Speaker 2: Peter Farrell in Sydney after he acquired a small piece
• 1:20
  Speaker 2: of sleep apnea tech from the company that he used
• 1:22
  Speaker 2: to work for and be Man.
• 1:23
  Speaker 1: Since then, Resmet has grown to make a whole range
• 1:26
  Speaker 1: of medical gear.
• 1:27
  Speaker 2: But of course they're most famous for their seapap machines,
• 1:29
  Speaker 2: which help people with sleep apnea to breathe better at night.
• 1:33
  Speaker 2: They also make masks, humidifiers, and sleep tracking tools and
• 1:36
  Speaker 2: jazzy boy. Snores are booming because Resme just released some
• 1:40
  Speaker 2: smashing results for FY twenty five.
• 1:42
  Speaker 1: YEP it's net profit jump thirty seven percent to one
• 1:44
  Speaker 1: point four billion US dollars.
• 1:46
  Speaker 2: And revenue climb ten percent to five point one bill.
• 1:48
  Speaker 1: So now they're increasing their share buybacks and lifting their
• 1:51
  Speaker 1: dividend by thirteen percent.
• 1:52
  Speaker 2: Fair to say, ResMed investors are snoozing very happily.
• 1:56
  Speaker 1: Yeah, and while there was fear that weight loss drugs
• 1:58
  Speaker 1: could kill the demand for seapap machines, ResMed reckon. This
• 2:01
  Speaker 1: is totally overblow.
• 2:02
  Speaker 2: And I guess, Juzi boy, the results really speak for themselves.
• 2:05
  Speaker 1: So what is the key learning here?
• 2:06
  Speaker 2: Sometimes the threat to your business can end up becoming
• 2:09
  Speaker 2: a new growth channel.
• 2:10
  Speaker 1: Yet this be man. Weight loss drugs like Ozenbig. We're
• 2:12
  Speaker 1: seen as a major risk to RESMD because losing weight
• 2:15
  Speaker 1: can improve sleep apnea symptoms.
• 2:17
  Speaker 2: But juzyboy, the opposite actually happened, didn't it.
• 2:19
  Speaker 1: It did. People started going to their doctors for weight
• 2:21
  Speaker 1: loss drugs and were being diagnosed with sleep issues.
• 2:24
  Speaker 2: Crazy, and they were getting prescribed with Resmed's devices too.
• 2:28
  Speaker 1: So instead of cannibalizing demand, these drugs are actually helping
• 2:31
  Speaker 1: identify more patients who need treatment.
• 2:33
  Speaker 2: In fact, research shows that eleven percent of patients on
• 2:36
  Speaker 2: weight loss drugs also start on treatment for their airways.
• 2:40
  Speaker 1: Like RESMD seebat machine.
• 2:41
  Speaker 2: So, Juzi boy, it's a handy reminder that in healthcare,
• 2:44
  Speaker 2: fixing one thing often uncovers another, and.
• 2:46
  Speaker 1: For ResMed, the boom in weight loss drugs might actually
• 2:48
  Speaker 1: be helping them.
• 2:49
  Speaker 2: For our second story, Figma, the design software has tripled
• 2:53
  Speaker 2: its market cap on its IPO debut in one of
• 2:56
  Speaker 2: the biggest first day pops for a US software company ever.
• 2:59
  Speaker 1: Go you good design software, be man. So what is
• 3:01
  Speaker 1: going on here? Right?
• 3:02
  Speaker 2: So? Figma was founded in twenty twelve and became famous
• 3:05
  Speaker 2: for its cloud based design software.
• 3:06
  Speaker 1: Which replaced old school file sharing designs.
• 3:09
  Speaker 2: I'll send you design file version one, you send me
• 3:11
  Speaker 2: back design file version one point one, and then I'll
• 3:14
  Speaker 2: send you back version one point two.
• 3:16
  Speaker 1: None of that with Figma. It's essentially like Google Docs,
• 3:19
  Speaker 1: but for designers with pantone color obsession and juzzy boy.
• 3:22
  Speaker 2: Since its launched, Figma has grown to over four million
• 3:24
  Speaker 2: users worldwide. But now Figma has listed on the NASDAC
• 3:27
  Speaker 2: late last week and popped to a market cap of
• 3:29
  Speaker 2: over forty five billion US dollars.
• 3:31
  Speaker 1: Pop that Adobe, It listed an issue price of thirty
• 3:34
  Speaker 1: three dollars per share. By the end of day one,
• 3:37
  Speaker 1: the shares closed at over one hundred and fifteen US
• 3:39
  Speaker 1: dollars per share.
• 3:40
  Speaker 2: In other words, more than two hundred and fifty percent
• 3:42
  Speaker 2: higher than its listing price, and.
• 3:43
  Speaker 1: That gives it the biggest first day pop for a
• 3:46
  Speaker 1: US software IPO, raising over a billion dollars in at
• 3:48
  Speaker 1: least thirty years.
• 3:50
  Speaker 2: Huge juzzy boy. So what's the key learning here?
• 3:52
  Speaker 1: Going public isn't just about high It's about managing supply
• 3:55
  Speaker 1: demand and setting a price based on what investors are
• 3:58
  Speaker 1: willing to pay.
• 3:58
  Speaker 2: In Figma's case, the company offered thirty six point nine
• 4:01
  Speaker 2: million shares to the public at a price of thirty
• 4:03
  Speaker 2: three bucks per share.
• 4:04
  Speaker 1: But the demand for the shares at that price was wild.
• 4:07
  Speaker 2: And the IPO was more than forty times over subscribe
• 4:10
  Speaker 2: and be man.
• 4:11
  Speaker 1: With that kind of frenzy, it usually causes a pop
• 4:13
  Speaker 1: with a share price rockets on the first day of trading,
• 4:15
  Speaker 1: and you may remember, be Man. A similar thing happened
• 4:17
  Speaker 1: with Airbnb in twenty twenty. It shares more than doubled
• 4:21
  Speaker 1: on day one of its listing.
• 4:22
  Speaker 2: Yes, they listed at sixty eight bucks per share, and
• 4:24
  Speaker 2: they finished that day at one hundred and forty six
• 4:27
  Speaker 2: dollars per year.
• 4:28
  Speaker 1: But now they're actually just below that one hundred and
• 4:30
  Speaker 1: forty six dollars share price.
• 4:31
  Speaker 2: So sometimes the day one price is more hype than
• 4:34
  Speaker 2: long term value.
• 4:35
  Speaker 1: The real challenge for companies like Figma is proving they're
• 4:38
  Speaker 1: worth the buzz. For our third and final story, Novo Nordisic,
• 4:42
  Speaker 1: the company behind Ozembia, has seen its market value slash
• 4:45
  Speaker 1: by over sixty billion euro after investors worry it's losing
• 4:49
  Speaker 1: in the obesity drug race. Another twist in the weight
• 4:52
  Speaker 1: loss was tell me more. Okay, So NVA notice is
• 4:55
  Speaker 1: the Danish farmer company. It's been kicking around since nineteen
• 4:58
  Speaker 1: twenty three.
• 4:58
  Speaker 2: And does it wait? It's fair to st they were
• 5:00
  Speaker 2: just ticking things over until more recently.
• 5:03
  Speaker 1: Yep. That's when Nva Nordisk developed a diabetes drug called Ozimpit,
• 5:07
  Speaker 1: and while it helped people manage type two diabetes, it
• 5:10
  Speaker 1: also helped people lose bucket loads of weight, and the
• 5:12
  Speaker 1: growth of the diabetes and weight loss drugs made Nova
• 5:15
  Speaker 1: Nordic the most valuable company in Europe for a hot
• 5:17
  Speaker 1: minute last year.
• 5:18
  Speaker 2: But joseboit late last week, Novo Nordice cut its full
• 5:21
  Speaker 2: year sales and profit forecasts for the second time this year,
• 5:24
  Speaker 2: might I add, and investors sped out their green juices.
• 5:27
  Speaker 2: The share price fell thirty percent in one day, and
• 5:29
  Speaker 2: why more than sixty billion euro from its value and
• 5:32
  Speaker 2: what was the reason? Well, weight loss drugs in the
• 5:34
  Speaker 2: US are growing very quickly. That's good, but Novo Nordisk
• 5:37
  Speaker 2: growth is slowing quickly as well. So jusei boy, it
• 5:40
  Speaker 2: seems like the competitive moat held by Novo Nordisk is
• 5:43
  Speaker 2: no longer moting.
• 5:44
  Speaker 1: So what is the key learning here?
• 5:45
  Speaker 2: A competitive moat is a company's ability to maintain its
• 5:48
  Speaker 2: edge over rivals. For example, it can be built on
• 5:51
  Speaker 2: being the first mover in a market, or it could
• 5:53
  Speaker 2: be based on IP like patents, or even the effort
• 5:56
  Speaker 2: and cost of switching products. Novo Nordice once had a
• 5:59
  Speaker 2: strong mote with Wegovi and Ozempi.
• 6:01
  Speaker 1: Yep. They were early, they were effective, and they had
• 6:03
  Speaker 1: their own IP.
• 6:04
  Speaker 2: But motes can shrink, especially.
• 6:06
  Speaker 1: When rivals like Eli Lily rock up with newer drugs
• 6:09
  Speaker 1: supposedly work better.
• 6:10
  Speaker 2: In Novo's case, its mote was weakened by two main threats.
• 6:13
  Speaker 1: Elai Lily roche Astrozenicat. They've all launched very similar products
• 6:17
  Speaker 1: to compete in the weight loss market.
• 6:18
  Speaker 2: And secondly, the US market has been flooded with generic
• 6:21
  Speaker 2: versions of the weight loss drugs that are often significantly cheaper.
• 6:25
  Speaker 1: In fact, prescription data from July this year showed that
• 6:27
  Speaker 1: ozempic slipped below fifty percent market share of the weight
• 6:30
  Speaker 1: loss market for the very first time.
• 6:32
  Speaker 2: So while Novo was once the poster child of the
• 6:34
  Speaker 2: weight loss revolution, it's now being bitten in the very race.
• 6:37
  Speaker 1: It helped us start fluxdam If you look at your
• 6:39
  Speaker 1: bank account every month and think where did my money
• 6:42
  Speaker 1: go this month? There is only one solution. It is
• 6:44
  Speaker 1: the Flux Budgeting tool breaks down your spending, tells you
• 6:46
  Speaker 1: how much you spending these different categories, so you may
• 6:48
  Speaker 1: shure to download the Flux app and check out the
• 6:50
  Speaker 1: budgeting tool.
• 6:51
  Speaker 2: Thanks for listening and we'll see you on Wednesday.